Study S000696

A Phase 2b, Double-Blind Study to Investigate the Effect of Retatrutide on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05936151
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 146
Start: 2023-07-20
Primary completion: 2025-10-01
Lead sponsor: Eli Lilly and Company
Conditions: Overweight or Obesity; CKD; Type 2 Diabetes
Interventions: DRUG:Retatrutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:J1I-MC-GZBU; OTHER:2023-504583-42-00; NIH:2023

Registered primary outcomes

Change from Baseline in Glomerular Filtration Rate (mGFR) [Baseline, Week 24]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0012093	Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. Heerspink HJL, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association	2026	Protocol	PMID 41160422 DOI	cites ClinicalTrials.gov:NCT05936151; registry reference DERIVED:41160422